- Advertisement -
- Advertisement -

Rhenman downplays risk of US price regulation of pharmaceuticals

- Advertisement -

Stockholm (HedgeNordic) – In September, shares of companies within healthcare and biotech saw another round of sharp declines. The Nasdaq Biotechnology Index dropped more than 11 percent during the month and has over the last two months experienced a drop of more than 20 percent. From the peak, the index is down in excess of 30 percent.

Henrik Rhenman (pictured), portfolio manager of Rhenman Healthcare Equity Long/Short, commented on the development in a video interview distributed by Rhenman & Partners:

“The decline of share prices within healthcare and biotech in September was significant. In particular, shares of biotech companies were badly hit. For a single month, these are the largest drops in the sector as far as I can recall and particularly noticeable given the weak numbers in August”, says Henrik Rhenman and continues:

“The sharp drops can be seen in the light of worries for the Chinese economy in August and concerns over a potential price regulation of the US market for pharmaceuticals in September.”

The question regarding a price regulation of pharmaceuticals in the US, a non-regulated market today, has been subject to discussions in the congress for decades according to Rhenman. It resurfaced in September when a company raised the price of a single drug by 5.000 percent. This event had presidential candidate Hillary Clinton, via a tweet, announcing that she intends to introduce price regulations for the US pharmaceuticals market.

Henrik Rhenman downplays the risk of a price regulation and sees limited effects should it become a reality.

“Our view on the price issue is that it creates short-term turbulence, due to the large media coverage, but that in the longer term, it will have limited effects. The health sector in the USA makes up 17.5% of the GDP. Price debate is only related to pharmaceuticals, which constitute 11% of the health sector. Therefore, the impact on the sector as a whole is relatively limited.”

Rhenman believes that valuations of companies within healthcare and biotech are low considering the underlying growth.

“P/E-ratios are now around 17 for the entire sector making it trading at a small premium to the S&P 500 which currently trades at a level of around 16.5. At the same time, companies within this sector are projecting much higher growth figures. I do not think there are reasons to be worried”, Rhenman concludes.

Subscribe to HedgeBrev, HedgeNordic’s weekly newsletter, and never miss the latest news!

Our newsletter is sent once a week, every Friday.

Jonathan Furelid
Jonathan Furelid
Jonathan Furelid is editor and hedge fund analyst at HedgeNordic. Having a background allocating institutional portfolios of systematic strategies at CTA-specialist RPM Risk & Portfolio Management, Mr. Furelid’s focus areas include sytematic macro and CTAs. Jonathan can be reached at: jonathan@hedgenordic.com

Latest Articles

Leveraging Opportunities in Credit Markets

Stockholm (HedgeNordic) – After several years of successful bond investing through a private investment company, Nicolai Wenckheim launched an alternative investment fund in March...

ATP’s Response to Changing Equity-Bond Correlations

Stockholm (HedgeNordic) – In 2022, the usual negative correlation between equities and bonds, essential for the construction of diversified portfolios, disappeared. This rare anomaly,...

Evolution in Hedge Fund Investing with LGT Collaboration

Stockholm (HedgeNordic) – Since Peter Ragnarsson assumed the role of Head of Alternatives at PRI Pensionsgaranti in 2015, the Swedish pension insurer has significantly...

Borea Expands Sustainability Focus with New Hire

Stockholm (HedgeNordic) – Norwegian fund boutique Borea Asset Management has expanded its management team with the hiring of Iselin Ahmer Solberg as a corporate...

Schroders Strengthens Nordic Client Team

Stockholm (HedgeNordic) – Schroders is expanding its client relationship capabilities in the Nordics with the appointment of Ludvig Löfving as a Client Director. He...

The Lynx Constellation Is Brightening Up

Stockholm (HedgeNordic) – Lynx Asset Management made headlines in late 2019 with the launch of its pure-play machine learning strategy, Constellation, as a standalone...

Allocator Interviews

Latest Articles

Man Institute Insights

Voices

Request for Proposal

- Advertisement -